Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of posttherapeutic imaging response to predict overall survival. Over 14 years, 948 patients with HCC were treated with radioembolization. Patients with baseline metastases, vascular invasion, multifocal disease, Child-Pugh > B7, and transplanted/resected were excluded. This created our homogeneous study cohort of 134 patients with Child-Pugh £ B7 and solitary HCC. Response (using European Association for Study of the Liver [EASL] and Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1] criteria) was associated with survival using Landmark and risk-of-death methodologies after reviewing 960 scans. In a subanalysis, survival times of responders were compared to those of patients with stable disease (SD) and progressive disease (PD). Uni/multivariate survival analyses were performed at each Landmark. At the 3-month Landmark, responders survived longer than nonresponders by EASL (hazard ratio [HR], 0.46; confidence interval [CI], 0.26-0.82; P 5 0.002) but not RECIST 1.1 criteria (HR, 0.70; CI, 0.37-1.32; P 5 0.32). At the 6-month Landmark, responders survived longer than nonresponders by EASL (HR, 0.32; CI, 0.15-0.77; P < 0.001) and RECIST 1.1 criteria (HR, 0.50; CI, 0.29-0.87; P 5 0.021). At the 12-month Landmark, responders survived longer than nonresponders by EASL (HR, 0.34; CI, 0.15-0.77; P < 0.001) and RECIST 1.1 criteria (HR, 0.52; CI 0.27-0.98; P 5 0.049). At 6 months, risk of death was lower for responders by EASL (P < 0.001) and RECIST 1.1 (P 5 0.0445). In subanalyses, responders lived longer than patients with SD or PD. EASL response was a significant predictor of survival at 3-, 6-, and 12-month Landmarks on uni/multivariate analyses. Conclusion: Response to radioembolization in patients with solitary HCC can prognosticate improved survival. EASL necrosis criteria outperformed RECIST 1.1 size criteria in predicting survival. The therapeutic objective of radioembolization should be radiologic response and not solely to prevent progression. (HEPATOLOGY 2018;67:873-883) 
Introduction
H epatocellular carcinoma (HCC) is now the fifth most common malignancy and the second most lethal cancer worldwide.
(1,2) While surgical treatments (transplantation/resection) are curative, many patients present with advanced disease for which sorafenib improves survival. (3, 4) Locoregional therapies, such as radioembolization, have a role in the management of HCC. (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) HCC usually develops in a background of cirrhosis. Liver dysfunction confounds overall survival (OS) studies because the malignancy-and/or cirrhosis-related complications can lead to death. While improvement in OS is the most important objective of cancer therapy, variables that predict survival are of clinical and research interest. Radiologic response has long been an integral factor that directs clinical care and is achieved earlier than the outcome needed for survival calculation (death). Hence, the ability of imaging response to predict and prognosticate survival has research and clinical implications. If an early response is able to predict survival in HCC, changes in management can be made early in the follow-up of these patients to achieve response. Also, if response can consistently predict survival, imaging response can be established as a biomarker and surrogate endpoint for OS in future studies. (16) Guarantee-time bias, the inherent statistical weakness of responder versus nonresponder survival analyses, has been reported. (17, 18) As recommended by statisticians, in this study we investigated response as a predictor of survival by performing time-dependent response analyses using Landmark and risk-of-death methods, thereby minimizing guarantee-time bias. (19) We also compared responders (complete response [CR] 1 partial response [PR] ) to stable disease (SD) and progressive disease (PD) to investigate if achieving disease control translated into clinical benefit or if there was improved survival only when exhibiting radiologic response (CR 1 PR); this information is of direct clinical relevance.
Patients and Methods
This study was compliant with the Health Insurance Portability and Accountability Act and approved by the Northwestern University Institutional Review Board. From 2002-2016, 948 patients with HCC were treated at our institution with radioembolization in our open-label treatment protocol (clinical trials: NCT00530010). (5) Patients were eligible for radioembolization if they exhibited unresectable HCC (determined by transplant surgery) and bilirubin < 3.0 mg/dL.
We excluded patients who: a) underwent liver transplantation or surgical resection (curative therapy), b) exhibited vascular invasion, extrahepatic metastases, or multifocal disease (confounding variables), or c) were Child-Pugh (CP) class > B7 (commonly used liver function cutoff for HCC studies) (Fig. 1) . This exclusion was performed in order to: a) create a homogeneous cohort with few confounding variables, b) minimize patients with negative tumor biology, c) increase the number of patients that would reach the 6-and 12-month landmarks, d) minimize the confounding effect of measuring response in the presence of treated and untreated disease, and e) address the limitation of guarantee-time bias. Patients who received curative surgical treatments were excluded to decrease the confounding effect of censoring to transplantation/resection on survival. This isolated our study population of 134 patients with solitary HCC (treated with radioembolization as the first therapy for HCC) whose survival outcomes were studied by analyzing 960 scans and assessing radiologic response (normalized to liver function, tumor size) to yttrium-90 (Y90) in a time-dependent manner. While radioembolization was the first treatment administered for HCC treatment in this group of patients, a minority of patients received other locoregional or systemic treatments at progression.
Patients were selected for radioembolization by a multidisciplinary team in our institutional weekly HCC conference. Unresectable tumors that met the following criteria were selected for transarterial therapy (radioembolization) over percutaneous therapy (radiofrequency ablation or microwave ablation): a) > 3 cm, b) location in proximity to diaphragm or large blood vessels, or c) transplant candidacy at time of treatment allocation (given risk of tract seeding with percutaneous methods).
Diagnostic criteria for HCC were defined by established institutional guidelines (arterial phase hyperenhancement and venous/delayed phase washout). (20) Baseline staging was performed by CP (liver function), United Network for Organ Sharing, and Barcelona Clinic Liver Cancer (BCLC). (20) RADIOEMBOLIZATION Radioembolization was performed using glass microspheres using a described technique. (21, 22) TIMING OF IMAGING/ LABORATORY EVALUATIONS Patients were followed using triphasic contrastenhanced computerized tomography (CT)/gadolinium-enhanced magnetic resonance imaging (MRI)/ liver functions at 1 month followed by 2-3 month intervals.
IMAGING TECHNIQUES
MRIs (our institutional standard) or CTs (in case of pacemakers/claustrophobia) were obtained. For each patient, the imaging modality (MRI versus CT) remained the same throughout the study period. We reviewed 960 CTs/MRIs for this analysis. The technique for MRI and CT is described below:
MRI
Abdomen/pelvis MRI protocol for liver imaging included transverse and coronal, T2-weighted, halfFourier acquisition, single-shot turbo spin echo, T2-weighted turbo spin-echo with fat suppression. Unenhanced and dynamic gadolinium-enhanced T1-weighted images were acquired by fat-suppressed gradient echo using shared prepulses (arterial/venous phases). Gadopentetate dimeglumine (Magnevist; Bayer HealthCare Pharmaceuticals, Berlin, Germany) was administered at a dose of 0.1 mmol/kg, followed by 20 mL saline flush (2 mL/second) with a power injector (Spectris; Medrad Inc., Warrendale, PA).
CT Imaging
Abdomen/pelvis CT for liver imaging included unenhanced arterial and portal venous phases according to our standard HCC protocol. Contrast-enhanced images were obtained after 40 seconds in the arterial phase and 70 seconds in the venous phase after 
METHODOLOGY OF RESPONSE ASSESSMENT
Response status was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, World Health Organization (WHO) size, and European Association for the Study of the Liver (EASL) necrosis criteria (Supporting Table 1 ). (3, 11, (23) (24) (25) (26) Patients with CR or PR were categorized as responders (R); those with SD or PD were categorized as nonresponders (NR). SD was conservatively designated an NR because without exhibiting decreased enhancement or size, we could not be certain that a lesion was not stable simply because of natural history in a slowly growing tumor. Patients developing new lesions, vascular invasion, and/or metastases were categorized as PD. New lesions were diagnosed by following established institutional guidelines (arterial phase hyperenhancement and venous/delayed phase washout). For new lesions where imaging was suspicious but not classic for HCC, a biopsy was performed.
Response assessment was performed by radiologists as part of routine clinical care with reporting of official measurements entered into the medical records. In order to obtain a second read as well as to maintain an element of blinding of the interventional radiologists to their own patients and their long-term outcomes, the 134-patient cohort was re-reviewed by an interventional radiologist who had not treated any of the patients (A.R.). For all 134 patients, size and tumor stage for all baseline and follow-up scans was performed.
RECIST 1.1, WHO, and EASL response guidelines were used to correlate response with survival. RECIST 1.1 (unidimensional) and WHO (bidimensional) guidelines have high intermethod agreement. Both methods were evaluated for the Landmark and risk-of-death methodologies. Only RECIST 1.1 (and not WHO) was used for the multivariate analysis to decrease multicollinearity artifacts. (11) Measurement of a single dimension of enhancing tissue (required by modified [m]RECIST) after Y90 may be challenging as tumors do not respond in a sequentially decreasing spherical fashion. A CR by mRECIST corresponds to a CR by EASL guidelines. mRECIST was also not used because the initiation of our study predates the introduction of this concept. (27) Hence, we opted to use EASL instead of mRECIST for this analysis although conceptually they are similar.
STATISTICAL ANALYSES AND SURVIVAL

Survival Analysis
The usual methods of plotting OS of R versus NR (best response) without analyzing data at multiple time points lead to biased estimates, invalid statistical tests, and misleading conclusions. (17, 28) Responders must live long enough for response to be observed (guarantee-time bias). This concept is relevant in HCC as the effect of response on survival is confounded by mortality from liver dysfunction. Because response is a timedependent variable not present at baseline, survival was correlated with response from two statistical methods correcting for guarantee-time bias. (29) In order to minimize the confounding effect of liver dysfunction, the analyses were performed in patients with CP B7.
LANDMARK
This method determines OS based on response status assessed at each specific time point. OS is calculated from the designated Landmark. Survival curves were plotted by Kaplan-Meier and compared using log-rank. (30) Because the Landmark method is recommended in oncology guidelines for R/NR analyses, 3-, 6-, and 12-month Landmarks were used; EASL, RECIST 1.1, and WHO response status were determined at each Landmark. (19) Fisher s exact test was used to compare CP class (B7 versus > B7) at the Landmark between to ensure R/NR groups were comparable at each time point, thereby eliminating better liver function as the explanation for better survival in the R group.
We also studied the effects of disease control versus progression by comparing survival outcomes of responders (CR 1 PR) versus SD versus PD to assess whether achieving a response was better than stable disease.
RISK-OF-DEATH
This method compares the rate or death of R versus NR in the 6 months following each Landmark. The chi-square test was used to compare rates of death.
Uni/Multivariate Analysis
Uni/multivariate analyses were performed using Kaplan-Meier and Cox proportional hazards model at each Landmark. This was done to analyze the effect of variables on survival, including response status, baseline tumor size, or liver function. Albumin and bilirubin levels were used to assess liver function at each landmark rather than CP to decrease multicollinearity. Hazard ratio (HR) estimates were based on simultaneous analysis of all variables. A significant P value of < 0.05 on univariate analyses was corrected for multiple comparisons using Bonferroni methodology. (31, 32) 
Effect of Tumor Size on Survival
Baseline tumor size was added as a variable to the uni/multivariate analyses to explore its effect on survival at each Landmark.
Results
BASELINE CHARACTERISTICS
The baseline characteristics of the 134 solitary patients with HCC are presented in Table 1 . Of these patients, 38 (28%) were < 65 years old; 85 (63%) were male individuals; 15 (11%) patients were BCLC 0, and 119 (89%) were BCLC A. No patient received curative surgical therapies (resection/transplantation).
POST-PROGRESSION THERAPIES AFTER 3-MONTH LANDMARK
While 9 and 11 patients progressed by EASL and RECIST 1.1, respectively, 13 in all demonstrated PD by either imaging criteria (patient overlap) at the 3-month Landmark; 7 patients received further locoregional and/or systemic therapy, (Supporting Table 2 ) while the other 6 patients succumbed to their disease without receiving any other treatments.
SURVIVAL ANALYSES
Data for the survival analyses are shown in Figure 2 .
Landmark Method RESPONDER VERSUS NONRESPONDER ANALYSIS
From the 3-month Landmark, median survival was 44 and 22 months for R and NR, respectively, by EASL (P 5 0.002); 34 and 27 months for WHO (P 5 0.51); and 51.6 and 46 months for RECIST 1.1 (P 5 0.32). From the 6-month Landmark, median survival was 33.5 and 13.9 months for R and NR, respectively, by EASL (P < 0.001); 61.5 and 23.6 months for WHO (P 5 0.027); and 56.1 and 36.3 months for RECIST 1.1 (P 5 0.021). From the 12-month Landmark, median survival for R and NR was 53.5 and 18.2 months, respectively, by EASL (P < 0.001); 56.7 and 31.8 months for WHO (P 5 0.0066); and 52.3 and 35.2 months for RECIST 1.1 (P 5 0.049).
At the 3-, 6-, and 12-month Landmarks, there was no difference in patients classified as CP B7 and CP > B7. This demonstrates that R and NR exhibited similar liver functions at each time point and that any survival difference was not attributable to better liver function (Supporting Table 3 ).
RESPONDER (CR 1 PR) VERSUS SD VERSUS PD ANALYSIS
From the 3-month Landmark, median survival was 44.3, 26.0, and 17.0 months for patients who were RECIST 1.1 criteria (P 5 0.0009). These data for WHO guidelines are also presented in Figure 2 .
Risk-of-Death
From the 3-month Landmark, death rates in R and NR were 2% and 4%, respectively, by EASL (P 5 0.618); they were 0% and 3% by RECIST 1.1 (P 5 0.3076). From the 6-month Landmark, the death rate in R and NR were 0% and 30%, respectively, by EASL (P < 0.0001); they were 2% and 12% by RECIST 1.1 (P 5 0.0445). From the 12-month Landmark, death rates in R and NR were 2% and 19%, respectively, by EASL (P 5 0.007); they were 2% and 13% by RECIST 1.1 (P 5 0.0649). These data for WHO guidelines are also presented in Figure 2 .
UNI/MULTIVARIATE ANALYSES
At the 3-month Landmark, univariate and multivariate analyses (Table 2) At the 12-month Landmark, univariate and multivariate analyses confirmed EASL response as a significant and independent prognosticator of survival. EASL response and baseline albumin were significant prognosticators of survival on univariate analysis.
EFFECT OF TUMOR SIZE ON SURVIVAL
Baseline tumor size was not a significant factor affecting survival on univariate analysis at the 6-and 12-month Landmarks ( Table 2 ).
Discussion
Survival is the gold-standard outcome in oncology. However, HCC is unique in that survival is dependent on the competing risks of death (malignancy, cirrhosis). (23) Patients with HCC routinely receive multiple different therapies with cross-over between treatments. Hence, identifying a survival benefit attributable to one therapy without prohibitively large studies is effectively impossible, suggesting that surrogates of survival are needed. The aim of this study was to investigate whether tumor response in a well-defined HCC population following radioembolization could be used as a predictor of survival. These data could help design future randomized studies validating response as a surrogate of survival.
Our study included 948 patients with HCC with radioembolization over a 14-year period. We identified a subgroup of 134 patients (CP B7) with solitary HCC and reviewed a total of 960 scans. This simplified the response analysis (one target lesion) and decreased the confounding effect of censoring to curative (transplantation/resection) and alternate therapies on survival; these patients only received radioembolization.
We used the Landmark and risk-of-death methods to mitigate guarantee-time bias and study the relationship of response and survival. Guarantee-time bias in the context of imaging response refers to the fact that patients who die early do not have an opportunity to enter the responder group. (19) This phenomenon guarantees a significantly shorter survival in nonresponders compared to responders. The Landmark method determines patient response status at a specified posttherapeutic time point. Survival is then estimated from that time point onward. Patients who die before the Landmark are excluded, minimizing confounding effects and permitting survival analysis in patients with favorable biology (liver function and tumor). The 3-, 6-, and 12-month (61 month) Landmarks were deemed clinically relevant. (28) We included the 3-month Landmark as a very early time point at which response or lack thereof permitted early changes in management for nonresponders. Finally, we assessed survival using risk-of-death, comparing rates of death of responders versus nonresponders in the 6 months following each Landmark.
Our data show that responders by EASL criteria live longer than nonresponders from the 3-month Landmark onwards. This was also confirmed on univariate and multivariate analyses at the 3-and 6-month Landmarks. This is in line with previously published data where the median time to EASL response is 1-2 months. (33) As patients have not had time to respond by RECIST 1.1 criteria (median time to RECIST and WHO response is 6-8 months), RECIST 1.1 response was not a significant prognostic indicator of survival at the 3-month Landmark. Hence, this subanalysis highlights the role of tumor enhancement in the early follow-up of these patients. This could impact management, and changes can be made early in the follow-up of these patients to achieve response.
Responders by EASL and RECIST 1.1 live longer than nonresponders from the 6-month and 12-month Landmark onwards, with data demonstrating that both enhancement and size guidelines predict survival. From the 12-month Landmark, responders by RECIST 1.1 (52-month median survival) exhibited 0.52 hazards of death when compared to nonresponders; whereas responders by EASL (53-month median survival) exhibited 0.34 hazards of death when compared to nonresponders.
This analysis highlights the role of enhancing tumor size (EASL) and whole lesion size (RECIST 1.1) at these time points. A decrease in the size of the whole lesion suggests favorable tumor biology (tumor is demonstrating necrosis, and the surrounding liver is able to regenerate to fill in the space created by the necrosed tumor). Multivariate analyses revealed that EASL response was a significant prognosticator of survival at the 3-and 6-month Landmarks.
Our method of assessing EASL response employed in this analysis has been published. (11) The most appropriate way of measuring the amount of enhancing tissue to assess response in HCC is still under investigation. The mRECIST guidelines are gaining popularity. Lencioni et al. (34) recently used prospectively collected data on patients treated with brivanib or placebo to evaluate the ability of mRECIST response in predicting survival. Out of 334 patients in that analysis, 28 achieved an objective response. Measurement of a single dimension of enhancing tissue (required by mRECIST) in a posttherapy tumor is difficult as tumors do not respond in a sequentially decreasing spherical fashion. As previously stated, a CR by mRECIST corresponds to a CR by EASL guidelines. Hence, we opted to use EASL instead of mRECIST for this analysis, especially given its known limitations with Y90. (35) Methodologies of assessing response using the amount/quantity of enhancing tissue should focus on concepts, such as quantitative EASL, as these have been shown to outperform other methodologies. (36, 37) However, such software tools are not currently available. Bruix et al. (38) have recently outlined the limitations response and highlighted the need for validating studies.
Our data demonstrate the interplay between response (CR/PR), SD, and PD. Patients exhibiting response at the 3-month Landmark by EASL guidelines and by EASL and RECIST 1.1 guidelines at the 6-month and 12-month Landmarks exhibited longer survival than those who had stable disease, which in turn had better survival than those with PD. Response and disease control were associated with improved survival. However, responders outperformed SD and PD. This may suggest that treatment should be continued/ repeated until response is achieved rather than observation and maintaining stability. (39) The risk-of-death analysis provides further evidence for improved survival in responders. Responders had lower rates of death using EASL criteria at the 6 and 12-month Landmarks. By RECIST 1.1, survival was significantly improved for responders when compared to nonresponders at 6 months. It also demonstrated a trend towards statistical significance at 12 months (P 5 0.065). The median time to RECIST/WHO response in intra-arterial therapy often exceeds 6 months. (5, 10) Unlike RECIST 1.1, EASL response occurs earlier after therapy; our data suggest that a lasting response at 12 months is a powerful predictor of patient outcome. (10) As smaller tumors may demonstrate a higher response rate compared to larger tumors, it is possible that responders survive longer than nonresponders because of smaller tumor size. On univariate and multivariate analyses, we found this not to be the case as baseline tumor size did not affect survival effect at the 6-month and 12-month Landmarks. Hence, the survival benefit in responders when compared to nonresponders is not explained by differences in tumor size.
Imaging response to various locoregional therapies in patients with HCC, including chemoembolization and percutaneous ablation, has been studied in multiple retrospective analyses. (40) Response to transarterial chemoembolization has been suggested as a biological selection criterion for liver transplantation. (41) A decrease in size of the treated tumor (RECIST 1.1) and a decrease in amount of enhancing tissue (EASL and mRECIST) following locoregional therapies (other than radioembolization) have demonstrated prognostic value. (42) The ability of tumor response to predict survival may simplify clinical trial strategy, with the focus of new treatments not only being to delay progression but also to elicit radiologic response. Early response by EASL guidelines, if prospectively validated, may serve as a surrogate for survival in clinical trials.
Strengths of this study include the incorporation of Landmark methodology, which minimizes uncontrolled/unknown confounding variables and embeds a "biological test-of-time." We applied three predetermined Landmarks, thereby permitting "early" (3-month), "intermediate" (6-month) , and "late" (12-month) biological tests-of-time. These methods minimized guarantee-time bias seen in R versus NR analyses and also permitted the assessment of response as a time-dependent covariate. Multiple statistical methods converged to the same conclusion, further strengthening the findings. (43) The analysis is robust, with 960 scans reviewed, translating to an average of seven scans per patient. Limitations include that this study establishes individual-level association; for trial-level association validating response as a surrogate of OS, randomized studies will be required. We studied a select group of solitary patients with HCC treated with radioembolization and who never underwent transplantation/resection. Although this approach decreased confounding variables, further analyses are needed. While radioembolization was the first treatment administered for HCC treatment in this group of patients, a minority of patients (n 5 7) who exhibited PD received other locoregional therapies, such as transarterial chemoembolization or radio frequency ablation, and/or systemic therapy, such as sorafenib (in cases of metastatic disease or vascular invasion). Finally, this analysis is only directly applicable to BCLC 0/A patients. Given that these patients were not deemed candidates for the first-line treatment recommended by guidelines, they were stage migrated to an arterial therapy, in this case radioembolization. Future Landmark studies will be needed to validate imaging response as a surrogate of survival in BCLC B disease treated with radioembolization or other locoregional therapies.
Independent of liver function and tumor size, radioembolization responders survive longer than nonresponders. Response prognosticates survival and is better than achieving disease stability; treatment should continue until response (PR/CR) is reached as long as liver functions are maintained. Our analysis provides evidence supporting the concept proposed by EASL (enhancing region size) for assessment of tumor response and may be considered an early prognosticator of survival.
(23) RECIST 1.1 and WHO (size) guidelines also have a role in survival prognostication. Prospective trials will be required to institute radiologic response as a surrogate of the gold-standard clinical endpoint (survival).
